{{Rsnum
|rsid=7144
|Gene=CD46
|Chromosome=1
|position=207794374
|Orientation=plus
|GMAF=0.3563
|Gene_s=CD46
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 18.2 | 46.4 | 35.5
| HCB | 2.2 | 29.1 | 68.7
| JPT | 1.8 | 22.5 | 75.7
| YRI | 12.1 | 47.1 | 40.7
| ASW | 23.6 | 45.5 | 30.9
| CHB | 2.2 | 29.1 | 68.7
| CHD | 1.9 | 23.1 | 75.0
| GIH | 9.9 | 45.5 | 44.6
| LWK | 11.3 | 60.4 | 28.3
| MEX | 29.8 | 49.1 | 21.1
| MKK | 21.6 | 41.8 | 36.6
| TSI | 15.8 | 44.6 | 39.6
| HapMapRevision=28
}}{{PMID Auto
|PMID=22357652
|Title=CD46 measles receptor polymorphisms influence receptor protein expression and primary measles vaccine responses in naive Australian children
|OA=1
}}

{{PMID Auto
|PMID=18483746
|Title=Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation.
|OA=1
}}

{{PMID Auto
|PMID=19861685
|Title=Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA}}
{{on chip | Illumina Human 1M}}
{{on chip | NatGeo2}}